Skip to main content

Table 2 Patient and treatment characteristics

From: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

  Median (years) Range (years)
Age 61 48 to 74
Time on tamoxifen 1.8 0.4 to 6.0
Time to recurrence 3.1 0.12 to 16.2
Time to death 5.9 0.26 to 15.7
Time of follow up 12.4 6.3 to 19.2